Interní Med. 2011; 13(1): 28-30

An obese patient at the doctor‘s surgery

MUDr.RNDr.Tomáš Brychta, Ph.D.1, MUDr.Svetlana Brychtová, Ph.D.2
1 NZZ Centrum léčby diabetu a obezity, Olomouc
2 Ústav patologické anatomie, LF UP Olomouc

The continuously increasing number of obese people in both the developed and developing world represents a growing health, social

and economic burden in the individual countries. Obesity accounts for 2–8 % of health care costs and 10–13 % of deaths in Europe. Virtually

all physicians must be prepared to fight obesity because obese individuals will represent an increasingly larger proportion of their

patients. Given the limited pharmacotherapy options, more attention is paid to the surgical treatment of obesity and the use of very

low calorie diets (VLCDs). A new group of anti-diabetic drugs base on incretin principle with a positively inpact no weight reduction are

discussed. The paper provides brief instructions on how to approach obese patients, how to examine and treat them.

Keywords: obesity, examining an obese patient, obesity treatment

Published: January 14, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brychta T, Brychtová S. An obese patient at the doctor‘s surgery. Interní Med. 2011;13(1):28-30.
Download citation

References

  1. Svačina S, Matoulek M, Lajka J. Výsledky aktuálního průzkumu výskytu obezity v České republice. Diabetologie Metabolismus Endokrinologie Výživa 2009, 12(Suppl.): 21.
  2. Management of Obesity in Adults: Europan Clinical Praktice Guidelines. Obesity Facts 2008; 1: 106-116.. Go to original source... Go to PubMed...
  3. Mullerová D, a kol. Obezita - prevence a léčba. Praha: Mladá fronta, a.s. 2009.
  4. Hajner V, a kol. Základy klinické obezitologie. Praha: Grada 2004.
  5. Svačina Š. Novinky ve farmakoterapii obezity. Farmakoterapie 2007; 4: 314-316.
  6. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.